TY  - JOUR
AB  - Adapted from the Canadian Healthcare Association’s submission to the House of Commons Standing Committee on Industry currently reviewing Bill C‐91, an Act to amend the Patent Act. Discusses the controversy surrounding this legislation, which extended patent protection to brand‐name drug manufacturers to 20 years before generic copies of pharmaceuticals can be introduced on to the market.
VL  - 10
IS  - 2
SN  - 1366-0756
DO  - 10.1108/13660759710171691
UR  - https://doi.org/10.1108/13660759710171691
PY  - 1997
Y1  - 1997/01/01
TI  - Health policy or intellectual property policy? The fight over Bill C‐91
T2  - Leadership in Health Services
PB  - MCB UP Ltd
SP  - 7
EP  - 10
Y2  - 2024/04/25
ER  -